US EditionGilead's CAR-T cell therapy shows promise in deadly brain cancer
- A Gilead Sciences-backed therapy shrank tumors in 62% of patients with recurrent glioblastoma, marking a rare success in treating this fatal brain cancer with few options.
- The therapy involves engineering patients' immune cells to target cancer cells, according to the study published in Nature Medicine.
- Most patients experienced manageable side effects, including fevers and confusion, for two to three days post-injection, according to Bagley.
- Historically, recurrent glioblastoma tumors do not respond well to treatments, indicating this result is unusual.
Insights by Ground AI
Does this summary seem wrong?
8 Articles
8 Articles
All
Left
Center
3
Right
4
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday.
·United Kingdom
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left0Leaning Right4Center3Last UpdatedBias Distribution57% Right
Bias Distribution
- 57% of the sources lean Right
57% Right
C 43%
R 57%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
